Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOC + Sarilumab vs Standard of Care for Early Treatment of COVID-19 Pneumonia
2020-002037-15Phase 2Completed
- Sponsor
- Cristina Avendaño Sola
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus pneumonia and coronavirus disease 2019 (COVID-19) comparing Standard of care + sarilumab with Standard of care alone (2 arms). Primary endpoint: Progression to severe respiratory failure, ICU admission, or death. Started May 2020; status: completed.
02
Drugs
sarilumab
03
Conditions
coronavirus pneumoniacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002037-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002037-15.